Evidence map›Paper›PMID 32703730›Full record

ArticleDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2020

Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver.

Alessio Aghemo, Mario Masarone, Sara Montagnese, Salvatore Petta, Francesca Romana Ponziani, Francesco Paolo Russo, Associazione Italiana Studio Fegato (AISF)

Open access · bronzeAbstract read
In one paragraph

Article in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. COVID-19: Has the Liver Been Spared?International journal of molecular sciences · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
  17. Sars-Cov-2 vaccination in liver transplant recipients: The 'holy grail' in a hostile environment.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
  18. COVID-19 and liver disease: where are we now?Nature reviews. Gastroenterology & hepatology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Alessio AghemoDivision of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
Mario MasaroneInternal Medicine and HepatologyDivision, Department of Medicine and Surgery "Scuola Medica Salernitana", University of Salerno, Baronissi (SA), Italy.
Sara MontagneseDipartimento di Medicina, Università di Padova, Italy.
Salvatore PettaSection of Gastroenterology and Hepatology, PROMISE, University of Palermo, Italy. Electronic address: salvatore.petta@unipa.it.
Francesca Romana PonzianiInternal Medicine, Gastroenterology and Hepatology Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversità Cattolica del Sacro Cuore - Rome - Italy.
Francesco Paolo RussoGastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital Padua, Italy.
Associazione Italiana Studio Fegato (AISF)
University of Padua · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Palermo · ITUniversity of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic had a huge impact on national and regional health systems. The impact of SARS-CoV-2 on the quality of care for patients with liver disease is still unknown.

aimsThe Italian Association for the Study of the Liver (AISF) conducted a survey to assess the impact of SARS-CoV-2 on hepatology units activities in Italy.

methodsA prospective web-based survey was proposed to all AISF active members. The survey was available online from April 8 2020, to May 3 2020, (lockdown phase in Italy).

results194 AISF members answered the questionnaire, most of whom were specialists in Gastroenterology (41%) or Internal Medicine (28%), and worked in Northern Italy (51%). 26% of hepatology wards had been converted into COVID-19 wards, and 33% had bed reductions. All hepatological activities, including the management of patients with decompensated liver disease, liver transplant and HCC had been significantly reduced/stopped. The number of physicians answering that their practices had not been modified ranged between 0.6% (for chronic hepatitis) to 47% (for the execution of paracentesis). The recorded answers were consistent among different regions, and did not show any north-south gradient

conclusionCOVID-19 outbreak significantly impacted on hepatological clinical activity. This survey can serve as a basis to compare the impact of future measures aimed at delivering an acceptable level of liver care during a national pandemic or crisis.

Indexed as

Ambulatory CareAntiviral AgentsBetacoronavirusCarcinoma, HepatocellularChronic DiseaseCoronavirus InfectionsCOVID-19Esophageal and Gastric VaricesGastroenterologyHepatitis B, ChronicHepatitis C, ChronicHospitalizationHumansItalyLiver CirrhosisLiver DiseasesAntiviral AgentsCovid-19HepatologySARS COV-2

Identifiers

PMID32703730
PMCPMC7351426
OpenAlexW3041884591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.